Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2742

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Protease activity in single-chain prekallikrein

Ivan Ivanov, Ingrid M. Verhamme, Mao-fu Sun, Bassem Mohammed, Qiufang Cheng, Anton Matafonov, S. Kent Dickeson, Kusumam Joseph, Allen P. Kaplan, David Gailani

Blood (2020) 135 (8): 558–567.

https://doi.org/10.1182/blood.2019002224

Published: 2020

Includes: Supplemental data

Journal Articles

A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies

Simon Timothy Abrams, PhD BSc, Ben Morton, MBChB, MD, Yasir Alhamdi, MBChB, PhD, Mohmad Alsabani, Zhenxing Cheng, Steven Lane, PhD, Ingeborg Welters, PhD, Guozheng Wang, MD PhD, Cheng-Hock Toh, MD

Blood (2019) 134 (Supplement_1): 440.

https://doi.org/10.1182/blood-2019-128493

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Aishath S Naeem, PhD, Winnie I Nguy, Svitlana Tyekucheva, PhD, Stacey M. Fernandes, BS, Vanessa Rai, BS, Kevin Ebata, PhD, Eliana B. Gomez, PhD, Barb J. Brandhuber, PhD, Stephen M. Rothenberg, MD PhD, Jennifer R Brown, MD PhD

Blood (2019) 134 (Supplement_1): 478.

https://doi.org/10.1182/blood-2019-124362

Published: 2019

Journal Articles

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Thomas J. Girard, Nina M. Lasky, Dhanalakshmi S. Anbukumar, George J. Broze, Jr.

Blood (2019) 134 (Supplement_1): 484.

https://doi.org/10.1182/blood-2019-130360

Published: 2019

Journal Articles

Characterization of the Interaction between Tissue Factor Pathway Inhibitor α (TFPIα) and Factor V Species

Teodolinda Petrillo, PhD, Cornelis Van 't Veer, PhD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 485.

https://doi.org/10.1182/blood-2019-130589

Published: 2019

Journal Articles

Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site

Vijay Kumar Reddy Kondreddy, MSc,PhD, Usha R. Pendurthi, PhD, Xiao Xu, John H. Griffin, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 481.

https://doi.org/10.1182/blood-2019-124976

Published: 2019

Journal Articles

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Takayuki Sasano, Saki Kushima, Matsushita Yutaka, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD

Blood (2019) 134 (Supplement_1): 1814.

https://doi.org/10.1182/blood-2019-123619

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Antonia Lopez-Girona, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka, Chin-Chun Lu, Mary Matyskiela, Gody Khambatta, Lilly Wong, Joshua Hansen, Daniel W. Pierce, Brian E. Cathers, James Carmichael

Blood (2019) 134 (Supplement_1): 1812.

https://doi.org/10.1182/blood-2019-124338

Published: 2019

Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD

Blood (2019) 134 (Supplement_1): 1869.

https://doi.org/10.1182/blood-2019-121805

Published: 2019

Journal Articles

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Loula Papageorgiou, Despina Fotiou, BMBS, MA, Patrick Van Dreden, PhD, Laurent Garderet, MD PhD, Meletios A. Dimopoulos, MD, Ismail Elalamy, MD PhD, Mohamad Mohty, MD PhD, Grigoris Gerotziafas, MD PhD

Blood (2019) 134 (Supplement_1): 1913.

https://doi.org/10.1182/blood-2019-126954

Published: 2019

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Marianne Kjalke, PhD, Mads Kjelgaard-Hansen, Søren Andersen, Ida Hilden

Blood (2019) 134 (Supplement_1): 3639.

https://doi.org/10.1182/blood-2019-122301

Published: 2019

Journal Articles

Modulation of Thrombin-Induced Platelet Activation By Defibrotide

Kristin N. Maher, MD PhD, Xu Han, BS, MS, Keith B. Neeves, PhD, Marvin T. Nieman, PhD, Jorge Di Paola, MD

Blood (2019) 134 (Supplement_1): 3614.

https://doi.org/10.1182/blood-2019-125945

Published: 2019

Journal Articles

Heme Overload Triggers Xanthine Oxidase Release and Mediates the Inflammatory Response

Heidi M Schmidt, BSE, Eric Kelley, PhD, Adam Straub, PhD

Blood (2019) 134 (Supplement_1): 3529.

https://doi.org/10.1182/blood-2019-130274

Published: 2019

Journal Articles

Abnormal Cytokine Production By Mast Cell Cultures from Sickle Cell Anemia Patients in Response to Inflammatory Stimuli and to Co-Culture with Eosinophils

Myriam Salazar-Terreros, PhDMSc, Kleber Yotsumoto Fertrin, MD PhD, Nicolas Moreno Reyes, PhD, Fernando Ferreira Costa, MD PhD, Carla F. Franco-Penteado, BSc, PhD

Blood (2019) 134 (Supplement_1): 3566.

https://doi.org/10.1182/blood-2019-129509

Published: 2019

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Protease activity in single-chain prekallikrein

A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Characterization of the Interaction between Tissue Factor Pathway Inhibitor α (TFPIα) and Factor V Species

Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Modulation of Thrombin-Induced Platelet Activation By Defibrotide

Heme Overload Triggers Xanthine Oxidase Release and Mediates the Inflammatory Response

Abnormal Cytokine Production By Mast Cell Cultures from Sickle Cell Anemia Patients in Response to Inflammatory Stimuli and to Co-Culture with Eosinophils

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only